Such expected results will warrant clinical testing of the BsAb strategy for patients with metastatic HER2-overexpressing cancers across a variety of cancer types, in particular cancers that respond to bevacizumab, such as colorectal cancer. The gene discussed is ERBB2; the disease is cancer.